NBSE
NeuBase Therapeutics, Inc.
NASDAQHealthcareBiotechnologyUS
Company Profile
CEO
Todd P. Branning
IPO Date
2004-05-28
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
NeuBase Therapeutics, Inc.
CEO
Todd P. Branning
IPO Date
2004-05-28
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 93,234 |
| $0.02 |
| 17 Mar 2023 | Branning Todd P. | Chief Financial Officer | A-Award | Acquired | 54,200 | $0.00 |
| 17 Mar 2023 | Stephan Dietrich A | director, 10 percent owner, officer: CEO and Director | A-Award | Acquired | 153,000 | $0.00 |
| 15 Feb 2023 | Stephan Dietrich A | director, 10 percent owner, officer: President and CEO | M-Exempt | Disposed | 655,000 | $0.00 |
| 15 Feb 2023 | Stephan Dietrich A | director, 10 percent owner, officer: President and CEO | M-Exempt | Acquired | 655,000 | $0.00 |
| 4 Nov 2022 | Branning Todd P. | Chief Financial Officer | A-Award | Acquired | 200,000 | $0.00 |
| 30 Sept 2022 | Stephan Dietrich A | CEO | M-Exempt | Disposed | 750,000 | $0.00 |
| 12 Sept 2022 | GOLDSTEIN DOV A MD | director | A-Award | Acquired | 37,600 | $0.60 |
| 12 Sept 2022 | Ende Eric J | director | A-Award | Acquired | 37,600 | $0.60 |